News
-
Aegis Therapeutics says that it has developed an intranasal hydromorphone for the treatment of acute pain and is making the formulation available for license. According to the company, the formulation, which is based on the… Read more . . .
-
Device manufacturer H&T Presspart has received its first European patent for the eMDI connected metered dose inhaler, the company said. The eMDI contains sensors that record inhaler usage and transmits data to Cohero Health’s BreatheSmart… Read more . . .
-
Boehringer Ingelheim, insurer Anthem, and Anthem’s research subsidiary HealthCore have announced the initiation of the AIRWISE study, which will compare Stiolto Respimat tiotropium bromide/olodaterol SMI to any commercially available combination of LAMA, LABA, and ICS… Read more . . .
-
According to Mundipharma, the Flutiform fluticasone propionate/formoterol fumarate k-haler breath-activated MDI has received marketing approval through the European decentralized procedure for the treatment of asthma in patients 12 and older. The company had submitted the… Read more . . .
-
Inhaler test equipment manufacturer Copley Scientific has launched The TPK 2100, a new model in its TPK series of critical flow controllers for the testing of dry powder inhalers. The company is also launching a… Read more . . .
-
DDL2017 delegates are being targeted by scammers, organizers warn. Callers claiming to be from the DDL organization have been phoning delegates and offering to book accommodations for the conference and then ask for credit card… Read more . . .
-
Pulmatrix has announced that its PUR1900 itraconazole DPI has received Qualified Infectious Disease Product (QIDP) designation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. PUR1900 received Orphan Drug designation in 2016 and… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has announced the appointment of former Nivalis Therapeutics leader Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Congleton was most recently President and CEO of Nivalis… Read more . . .
-
The 700-plus OINDP specialists expected to convene at the Edinburgh International Conference Centre December 6-8 for this year’s Drug Delivery to the Lungs (DDL) meeting will notice a few small changes designed to further the… Read more . . .
-
Synairgen has announced that it is considering development of its SNG001 inhaled interferon beta for the treatment of COPD. SNG001 was previously in development for the prevention of exacerbations caused by viral lung infections in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.